MNOV MediciNova Inc.

6.50
-0.01  -0%
Previous Close 6.51
Open 6.45
Price To book 6.77
Market Cap 234654765
Shares 36,100,733
Volume 64,730
Short Ratio 29.27
Av. Daily Volume 147,993

SEC filingsSee all SEC filings

  1. 8-K - Current report 171192999
  2. UPLOAD [Cover] - SEC-generated letter
  3. 8-K - Current report 171160725
  4. 8-K - Current report 171149871
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171149233

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released October 28, 2017 at Joint ECTRIMS – ACTRIMS meeting. Primary endpoint met.
MN-166
Progressive multiple sclerosis (progressive MS)
Phase 2 planned
MN-001
NASH (nonalcoholic steatohepatitis)
Phase 2 completion of enrollment noted September 19, 2017. Final data due 1Q 2018.
MN-166
Opioid dependence
Phase 2 interim data released April 2016
MN-166
Amyotrophic lateral sclerosis (ALS)

Latest News

  1. MNOV: Positive Topline Results for MN-166 in P2 ALS Study
  2. MediciNova stock up more than 50% on positive trial results
  3. MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS
  4. Is MediciNova Inc (MNOV) Cheap And High Growth?
  5. MediciNova Appoints Hideki Nagao to its Board of Directors
  6. MediciNova Announces Collaboration with the U.S. Department of Veterans Affairs and Oregon Health & Science University to Evaluate MN-166 (ibudilast) in Methamphetamine Use Disorder
  7. Is MediciNova Inc (MNOV) Undervalued?
  8. MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA
  9. MNOV: Positive Results in Phase 2b Study of MN-166 in Progressive MS
  10. MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile
  11. MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability
  12. MediciNova, Upcoming Phase II Data Presentation, Ibudilast Review
  13. MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
  14. MediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New York
  15. MNOV: MN-166 Shows Activity in Preclinical Brain Cancer Study

SEC Filings

  1. 8-K - Current report 171192999
  2. UPLOAD [Cover] - SEC-generated letter
  3. 8-K - Current report 171160725
  4. 8-K - Current report 171149871
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171149233
  6. EFFECT - Notice of Effectiveness 171116011
  7. CORRESP [Cover] - Correspondence
  8. S-3 - Registration statement under Securities Act of 1933 171098283
  9. 8-K - Current report 171074411
  10. 8-K - Current report 17984265